{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:03:35Z","timestamp":1792047815514,"version":"4.4.0"},"reference-count":172,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":344,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the implementation of effective treatments. Therefore, there is a crucial need for appropriate preclinical models to understand the biological basis of their cardiotoxicity. This scientific statement summarizes the preclinical models hitherto used, from in vitro two- and three-dimensional human systems to small and large animals, to pinpoint the molecular mechanisms behind the cardiotoxicity of new-generation anticancer therapies, particularly immunotherapies, and to develop potential cardioprotective strategies. Furthermore, it discusses how preclinical models have contributed to the provocative concept of heart failure being potentially tumorigenic and how the discovery of drugs with both anticancer and cardioprotective actions has revealed a common mechanistic basis for heart failure and cancer. Finally, it discusses the existing gaps between preclinical models and clinical observations in patients, how these discrepancies affect regulatory pathways and the drug development process in cardio-oncology and provides recommendations for closing these gaps.<\/jats:p>","DOI":"10.1002\/ejhf.3636","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T02:34:11Z","timestamp":1741746851000},"page":"1028-1046","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Update on Preclinical Models of Cancer Therapy-Related Cardiac Dysfunction: Challenges and Perspectives. A Scientific Statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart"],"prefix":"10.1093","volume":"27","author":[{"given":"Alessandra","family":"Ghigo","sequence":"first","affiliation":[{"name":"Molecular Biotechnology Center Guido Tarone, Department of Molecular Biotechnology and Health Sciences, University of Torino , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[{"name":"Cardiac, Vascular, and Thoracic Department, IRCCS Ospedale Policlinico San Martino , Genoa ,","place":["Italy"]},{"name":"Department of Internal Medicine, University of Genova , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Asnani","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Bertero","sequence":"additional","affiliation":[{"name":"Cardiac, Vascular, and Thoracic Department, IRCCS Ospedale Policlinico San Martino , Genoa ,","place":["Italy"]},{"name":"Department of Internal Medicine, University of Genova , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Cardiovascular Institute, Thorax Center, Department of Cardiology, Erasmus Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Athens University Hospital Attikon, National and Kapodistrian University of Athens Medical School , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Program of Cardiovascular Diseases, Foundation for Applied Medical Research (CIMA), Department of Cardiology, Cl\u00ednica Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), Universidad de Navarra , Pamplona ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Heymans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, CARIM Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre , Maastricht ,","place":["The Netherlands"]},{"name":"Centre of Cardiovascular Research, University of Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares , Madrid ,","place":["Spain"]},{"name":"Cardiology Department, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz Hospital , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Cardiology Department, La Paz University Hospital , Madrid ,","place":["Spain"]},{"name":"IdiPAZ research Institute , Madrid ,","place":["Spain"]},{"name":"Cardiology Department, Quironsalud Madrid University Hospital , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Lyon","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Centre of Excellence, Royal Brompton Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Pollesello","sequence":"additional","affiliation":[{"name":"Content and Communication, Branded Products, Orion Pharma , Espoo ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Rakisheva","sequence":"additional","affiliation":[{"name":"Department of Cardiology, City Cardiology Center , Almaty ,","place":["Kazakhstan"]},{"name":"Department of Cardiology, Qonaev City Hospital , Almaty ,","place":["Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Stellos","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Research, Medical Faculty Mannheim, Heidelberg University , Mannheim ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg\/Mannheim , Mannheim ,","place":["Germany"]},{"name":"Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University , Newcastle upon Tyne ,","place":["UK"]},{"name":"Medizinische Klinik I, Department of Cardiology, Angiology, Haemostaseology and Intensive Care Medicine, University Hospital Mannheim of the Heidelberg University , Mannheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Streckfuss-B\u00f6meke","sequence":"additional","affiliation":[{"name":"Clinic for Cardiology and Pneumology, Georg-August University G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]},{"name":"Medical Clinic I, Cardiology and Angiology, Justus-Liebig-University , Giessen ,","place":["Germany"]},{"name":"Institute of Pharmacology and Toxicology, University of W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]},{"name":"Comprehensive Heart Failure Center W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences (DISMET), Center for Basic and Clinical Immunology Research (CISI), Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Interdepartmental Hypertension Research Center (CIRIAPA), Federico II University , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Van Rooij","sequence":"additional","affiliation":[{"name":"Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]},{"name":"Department of Cardiology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Center for Heart Diseases, University Hospital, Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome , Rome ,","place":["Italy"]},{"name":"Cardiology, San Raffaele Cassino Hospital , Cassino ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Van Linthout","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health at Charit\u00e9-Universit\u00e4tsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT) , Berlin ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), Partner site Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"2026080801412374700_ejhf3636-bib-0001","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080801412374700_ejhf3636-bib-0002","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/RES.0000000000000473","article-title":"Preclinical models of cancer therapy-associated cardiovascular toxicity: A scientific statement from the American Heart Association","volume":"129","author":"Asnani","year":"2021","journal-title":"Circ Res"},{"key":"2026080801412374700_ejhf3636-bib-0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54669","article-title":"Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010","volume":"6","author":"Larsen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026080801412374700_ejhf3636-bib-0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080801412374700_ejhf3636-bib-0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaccao.2023.08.003","article-title":"Priorities in cardio-oncology basic and translational science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Salloum","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026080801412374700_ejhf3636-bib-0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003584","article-title":"Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging","volume":"9","author":"Farhad","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080801412374700_ejhf3636-bib-0007","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/cvr\/cvaa222","article-title":"Cardiac dysfunction in cancer patients: Beyond direct cardiomyocyte damage of anticancer drugs: Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart","volume":"116","author":"Tocchetti","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0008","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","article-title":"Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy","volume":"99","author":"Ozcelik","year":"2002","journal-title":"Proc Natl Acad Sci U\u2009S\u2009A"},{"key":"2026080801412374700_ejhf3636-bib-0009","doi-asserted-by":"crossref","first-page":"H1271","DOI":"10.1152\/ajpheart.00517.2014","article-title":"ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity","volume":"309","author":"Belmonte","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026080801412374700_ejhf3636-bib-0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11886-020-01325-x","article-title":"Pluripotent stem cell modeling of anticancer therapy-induced cardiotoxicity","volume":"22","author":"Lyra-Leite","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2026080801412374700_ejhf3636-bib-0011","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","article-title":"Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer","volume":"139","author":"Kitani","year":"2019","journal-title":"Circulation"},{"key":"2026080801412374700_ejhf3636-bib-0012","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/cvr\/cvad012","article-title":"PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications","volume":"119","author":"Xu","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0013","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","article-title":"Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing","volume":"32","author":"Medeiros","year":"2018","journal-title":"Blood Rev"},{"key":"2026080801412374700_ejhf3636-bib-0014","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1161\/CIRCRESAHA.123.323683","article-title":"Integrated stress response potentiates ponatinib-induced cardiotoxicity","volume":"134","author":"Yan","year":"2024","journal-title":"Circ Res"},{"key":"2026080801412374700_ejhf3636-bib-0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/CIRCRESAHA.122.321504","article-title":"Ponatinib drives cardiotoxicity by S100A8\/A9-NLRP3-IL-1\u03b2 mediated inflammation","volume":"132","author":"Tousif","year":"2023","journal-title":"Circ Res"},{"key":"2026080801412374700_ejhf3636-bib-0016","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jacbts.2017.12.007","article-title":"Increased afterload augments sunitinib-induced cardiotoxicity in an engineered cardiac microtissue model","volume":"3","author":"Truitt","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2026080801412374700_ejhf3636-bib-0017","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"2026080801412374700_ejhf3636-bib-0018","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026080801412374700_ejhf3636-bib-0019","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular manifestations from therapeutic radiation: A multidisciplinary expert consensus statement from the International Cardio-Oncology Society","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026080801412374700_ejhf3636-bib-0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2021.01.023","article-title":"Characterization of cardiovascular injury in mice following partial-heart irradiation with clinically relevant dose and fractionation","volume":"157","author":"Lee","year":"2021","journal-title":"Radiother Oncol"},{"key":"2026080801412374700_ejhf3636-bib-0021","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00395-013-0385-6","article-title":"Ionizing radiation regulates cardiac Ca handling via increased ROS and activated CaMKII","volume":"108","author":"Sag","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0022","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of anticancer drugs: Molecular mechanisms and strategies for cardioprotection","volume":"9","author":"Morelli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026080801412374700_ejhf3636-bib-0023","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080801412374700_ejhf3636-bib-0024","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune\u2009checkpoint\u2009inhibitors","volume":"74","author":"Ball","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0025","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080801412374700_ejhf3636-bib-0026","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"2026080801412374700_ejhf3636-bib-0027","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026080801412374700_ejhf3636-bib-0028","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: A nationwide Danish study","volume":"42","author":"D'Souza","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080801412374700_ejhf3636-bib-0029","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2026080801412374700_ejhf3636-bib-0030","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080801412374700_ejhf3636-bib-0031","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer \u2013 a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080801412374700_ejhf3636-bib-0032","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-023-00986-9","article-title":"Immune checkpoints in cardiac physiology and pathology: Therapeutic targets for heart failure","volume":"21","author":"Gergely","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0033","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/cvr\/cvz025","article-title":"T cell checkpoint regulators in the heart","volume":"115","author":"Grabie","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0034","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"2026080801412374700_ejhf3636-bib-0035","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"2026080801412374700_ejhf3636-bib-0036","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1038\/s41467-023-41066-3","article-title":"Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects","volume":"14","author":"Cortellino","year":"2023","journal-title":"Nat Commun"},{"key":"2026080801412374700_ejhf3636-bib-0037","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux","year":"2023","journal-title":"Nat Med"},{"key":"2026080801412374700_ejhf3636-bib-0038","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.abq6990","article-title":"The future of engineered immune cell therapies","volume":"378","author":"Irvine","year":"2022","journal-title":"Science"},{"key":"2026080801412374700_ejhf3636-bib-0039","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: The evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"2026080801412374700_ejhf3636-bib-0040","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801412374700_ejhf3636-bib-0041","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026080801412374700_ejhf3636-bib-0042","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s44321-024-00055-9","article-title":"Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models","volume":"16","author":"Jamali","year":"2024","journal-title":"EMBO Mol Med"},{"key":"2026080801412374700_ejhf3636-bib-0043","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"2026080801412374700_ejhf3636-bib-0044","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41551-023-01084-4","article-title":"Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel","volume":"7","author":"Li","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"2026080801412374700_ejhf3636-bib-0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176009","article-title":"Roles of IL-1 in cancer: From tumor progression to resistance to targeted therapies","volume":"21","author":"Gelfo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026080801412374700_ejhf3636-bib-0046","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2026080801412374700_ejhf3636-bib-0047","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0048","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.jacc.2020.02.070","article-title":"Cardiac events associated with chimeric antigen receptor T-cells (CAR-T): A VigiBase perspective","volume":"75","author":"Salem","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0049","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell\u2009therapy","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026080801412374700_ejhf3636-bib-0050","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"2026080801412374700_ejhf3636-bib-0051","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0052","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.691064","article-title":"An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: A single-centre retrospective study","volume":"11","author":"Qi","year":"2021","journal-title":"Front Oncol"},{"key":"2026080801412374700_ejhf3636-bib-0053","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/bloodadvances.2023009766","article-title":"Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Adv"},{"key":"2026080801412374700_ejhf3636-bib-0054","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","article-title":"Incidence of MACE in patients treated with CAR-T cell therapy: A prospective study","volume":"5","author":"Lefebvre","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026080801412374700_ejhf3636-bib-0055","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur Heart J"},{"key":"2026080801412374700_ejhf3636-bib-0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102504","article-title":"Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: A prospective cohort study","volume":"69","author":"Korell","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026080801412374700_ejhf3636-bib-0057","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"2026080801412374700_ejhf3636-bib-0058","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","article-title":"Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock","volume":"363","author":"Pathan","year":"2004","journal-title":"Lancet"},{"key":"2026080801412374700_ejhf3636-bib-0059","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: Current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front Immunol"},{"key":"2026080801412374700_ejhf3636-bib-0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026080801412374700_ejhf3636-bib-0061","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"2026080801412374700_ejhf3636-bib-0062","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nature Med"},{"key":"2026080801412374700_ejhf3636-bib-0063","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11095-023-03644-4","article-title":"An in silico platform to predict cardiotoxicity risk of anti-tumor drug combination with hiPSC-CMs based in vitro study","volume":"41","author":"Sang","year":"2024","journal-title":"Pharm Res"},{"key":"2026080801412374700_ejhf3636-bib-0064","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/cvr\/cvz018","article-title":"hiPSCs in cardio-oncology: Deciphering the genomics","volume":"115","author":"Pinheiro","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0065","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00204-020-02711-8","article-title":"GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: Establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes","volume":"94","author":"Karhu","year":"2020","journal-title":"Arch Toxicol"},{"key":"2026080801412374700_ejhf3636-bib-0066","doi-asserted-by":"crossref","DOI":"10.1038\/srep25333","article-title":"Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes","volume":"6","author":"Maillet","year":"2016","journal-title":"Sci Rep"},{"key":"2026080801412374700_ejhf3636-bib-0067","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ymthe.2020.12.035","article-title":"Telomerase therapy attenuates cardiotoxic effects of doxorubicin","volume":"29","author":"Chatterjee","year":"2021","journal-title":"Mol Ther"},{"key":"2026080801412374700_ejhf3636-bib-0068","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00395-022-00918-7","article-title":"Doxorubicin induces cardiotoxicity in a pluripotent stem cell model of aggressive B cell lymphoma cancer patients","volume":"117","author":"Haupt","year":"2022","journal-title":"Basic Res Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0069","article-title":"Modeling cardiotoxicity in pediatric oncology patients using patient-specific iPSC-derived cardiomyocytes reveals downregulation of cardioprotective microRNAs","volume":"12","author":"Reinal","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"2026080801412374700_ejhf3636-bib-0070","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1093\/eurheartj\/ehac337","article-title":"A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity","volume":"43","author":"Lu","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080801412374700_ejhf3636-bib-0071","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00392-020-01636-7","article-title":"Onco-cardiology: Consensus paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology","volume":"109","author":"Rassaf","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0072","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"2026080801412374700_ejhf3636-bib-0073","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2015.00059","article-title":"Excitation-contraction coupling of human induced pluripotent stem cell-derived cardiomyocytes","volume":"3","author":"Kane","year":"2015","journal-title":"Front Cell Dev Biol"},{"key":"2026080801412374700_ejhf3636-bib-0074","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abd1817","article-title":"Dynamic loading of human engineered heart tissue enhances contractile function and drives a desmosome-linked disease phenotype","volume":"13","author":"Bliley","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026080801412374700_ejhf3636-bib-0075","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.116.024145","article-title":"Defined engineered human myocardium with advanced maturation for applications in heart failure modeling and repair","volume":"135","author":"Tiburcy","year":"2017","journal-title":"Circulation"},{"key":"2026080801412374700_ejhf3636-bib-0076","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaccao.2023.03.012","article-title":"Evaluation of senescence and its prevention in doxorubicin-induced cardiotoxicity using dynamic engineered heart tissues","volume":"5","author":"Linders","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026080801412374700_ejhf3636-bib-0077","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12964-022-00916-1","article-title":"Effects of macrophages on the proliferation and cardiac differentiation of human induced pluripotent stem cells","volume":"20","author":"Long","year":"2022","journal-title":"Cell Commun Signal"},{"key":"2026080801412374700_ejhf3636-bib-0078","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.yjmcc.2021.12.001","article-title":"A roadmap for the characterization of energy metabolism in human cardiomyocytes derived from induced pluripotent stem cells","volume":"164","author":"Emanuelli","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0079","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41586-018-0016-3","article-title":"Advanced maturation of human cardiac tissue grown from pluripotent stem cells","volume":"556","author":"Ronaldson-Bouchard","year":"2018","journal-title":"Nature"},{"key":"2026080801412374700_ejhf3636-bib-0080","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1161\/RES.0000000000000291","article-title":"Use of human induced pluripotent stem cell-derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing: A scientific statement from the American Heart Association","volume":"125","author":"Gintant","year":"2019","journal-title":"Circ Res"},{"key":"2026080801412374700_ejhf3636-bib-0081","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.stemcr.2023.05.004","article-title":"Nutritional requirements of human induced pluripotent stem cells","volume":"18","author":"Lyra-Leite","year":"2023","journal-title":"Stem Cell Reports"},{"key":"2026080801412374700_ejhf3636-bib-0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100213","article-title":"An updated protocol for the cost-effective and weekend-free culture of human induced pluripotent stem cells","volume":"2","author":"Lyra-Leite","year":"2021","journal-title":"STAR Protoc"},{"key":"2026080801412374700_ejhf3636-bib-0083","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/CIRCRESAHA.119.314996","article-title":"Physiological biomimetic culture system for pig and human heart slices","volume":"125","author":"Ou","year":"2019","journal-title":"Circ Res"},{"key":"2026080801412374700_ejhf3636-bib-0084","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1093\/cvr\/cvad141","article-title":"Contractility measurements for cardiotoxicity screening with ventricular myocardial slices of pigs","volume":"119","author":"Shi","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282859","article-title":"Using cultured canine cardiac slices to model the autophagic flux with doxorubicin","volume":"18","author":"Boukhalfa","year":"2023","journal-title":"PLoS One"},{"key":"2026080801412374700_ejhf3636-bib-0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115213","article-title":"Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity","volume":"406","author":"Miller","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026080801412374700_ejhf3636-bib-0087","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010189","article-title":"Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase","volume":"6","author":"Liu","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026080801412374700_ejhf3636-bib-0088","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jat.2843","article-title":"Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish","volume":"34","author":"Zhu","year":"2014","journal-title":"J Appl Toxicol"},{"key":"2026080801412374700_ejhf3636-bib-0089","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1161\/CIRCRESAHA.111.255695","article-title":"A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity","volume":"109","author":"Cheng","year":"2011","journal-title":"Circ Res"},{"key":"2026080801412374700_ejhf3636-bib-0090","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/cvr\/cvz006","article-title":"Ponatinib-induced cardiotoxicity: Delineating the signalling mechanisms and potential rescue strategies","volume":"115","author":"Singh","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0091","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-pharmtox-030620-104842","article-title":"Preventing and treating anthracycline cardiotoxicity: New insights","volume":"61","author":"Sawicki","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026080801412374700_ejhf3636-bib-0092","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-021-06427-w","article-title":"Trastuzumab does not bind rat or mouse ErbB2\/neu: Implications for selection of non-clinical safety models for trastuzumab-based therapeutics","volume":"191","author":"Lewis Phillips","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2026080801412374700_ejhf3636-bib-0093","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136817","article-title":"Embryonic lethality in homozygous human Her-2 transgenic mice due to disruption of the Pds5b gene","volume":"10","author":"Yong","year":"2015","journal-title":"PLoS One"},{"key":"2026080801412374700_ejhf3636-bib-0094","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080801412374700_ejhf3636-bib-0095","article-title":"TNF-alpha inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"2026080801412374700_ejhf3636-bib-0096","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s43018-020-0039-1","article-title":"A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy","volume":"1","author":"Amgalan","year":"2020","journal-title":"Nat Cancer"},{"key":"2026080801412374700_ejhf3636-bib-0097","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","article-title":"Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth","volume":"138","author":"Li","year":"2018","journal-title":"Circulation"},{"key":"2026080801412374700_ejhf3636-bib-0098","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1093\/cvr\/cvab370","article-title":"Animal models and animal-free innovations for cardiovascular research: Current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart","volume":"118","author":"Velden","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0099","article-title":"Bovine model of doxorubicin-induced cardiomyopathy","volume":"2011","author":"Bartoli","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"2026080801412374700_ejhf3636-bib-0100","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cardfail.2012.03.005","article-title":"Dietary omega-3 supplementation exacerbates left ventricular dysfunction in an ovine model of anthracycline-induced cardiotoxicity","volume":"18","author":"Carbone","year":"2012","journal-title":"J Card Fail"},{"key":"2026080801412374700_ejhf3636-bib-0101","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.587149","article-title":"The effects of repeat-dose doxorubicin on cardiovascular functional endpoints and biomarkers in the telemetry-equipped Cynomolgus monkey","volume":"8","author":"Engwall","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026080801412374700_ejhf3636-bib-0102","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jacc.2018.11.046","article-title":"Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity","volume":"73","author":"Galan-Arriola","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0103","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/cvr\/cvab053","article-title":"Coronary microcirculation damage in anthracycline cardiotoxicity","volume":"118","author":"Galan-Arriola","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0104","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jcmg.2019.10.020","article-title":"Myocardial extracellular and cardiomyocyte volume expand after doxorubicin treatment similar to adjuvant breast cancer therapy","volume":"13","author":"Melendez","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080801412374700_ejhf3636-bib-0105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ehf2.12277","article-title":"Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy","volume":"5","author":"Muehlberg","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026080801412374700_ejhf3636-bib-0106","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.121.012459","article-title":"Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: A longitudinal cardiac resonance imaging study during 2\u2009years of follow-up","volume":"14","author":"Giusca","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080801412374700_ejhf3636-bib-0107","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jcmg.2020.01.017","article-title":"T2 mapping identifies early anthracycline-induced cardiotoxicity in elderly patients with cancer","volume":"13","author":"Martin-Garcia","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080801412374700_ejhf3636-bib-0108","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/cvr\/cvaa181","article-title":"Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity","volume":"117","author":"Galan-Arriola","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0109","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013754","article-title":"Reverse cardio-oncology: Cancer development in patients with cardiovascular disease","volume":"9","author":"Aboumsallem","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026080801412374700_ejhf3636-bib-0110","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaccao.2021.11.007","article-title":"Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort","volume":"4","author":"Bertero","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026080801412374700_ejhf3636-bib-0111","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead073","article-title":"Association between heart failure and the incidence of cancer: A systematic review and meta-analysis","volume":"3","author":"Jaiswal","year":"2023","journal-title":"Eur Heart J Open"},{"key":"2026080801412374700_ejhf3636-bib-0112","article-title":"Pressure overload-induced cardiac hypertrophy stimulates tumor growth in tumor-prone ApcMin mice","volume":"16","author":"Wit","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2026080801412374700_ejhf3636-bib-0113","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"2026080801412374700_ejhf3636-bib-0114","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.120.046471","article-title":"Early cardiac remodeling promotes tumor growth and metastasis","volume":"142","author":"Avraham","year":"2020","journal-title":"Circulation"},{"key":"2026080801412374700_ejhf3636-bib-0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417367","article-title":"Heart failure promotes cancer progression in an integrin \u03b21-dependent manner","volume":"24","author":"Langier Goncalves","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026080801412374700_ejhf3636-bib-0116","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/cvr\/cvae038","article-title":"Heart failure-induced microbial dysbiosis contributes to colonic tumour formation in mice","volume":"120","author":"Wit","year":"2024","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0117","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaccao.2023.10.002","article-title":"Heart failure post-myocardial infarction promotes mammary tumor growth through the NGF-TRKA pathway","volume":"6","author":"Tani","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026080801412374700_ejhf3636-bib-0118","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41591-020-0964-7","article-title":"Myocardial infarction accelerates breast cancer via innate immune reprogramming","volume":"26","author":"Koelwyn","year":"2020","journal-title":"Nat Med"},{"key":"2026080801412374700_ejhf3636-bib-0119","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cac2.12185","article-title":"Evaluation of renal cancer progression in a mouse model of heart failure","volume":"41","author":"Shi","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"2026080801412374700_ejhf3636-bib-0120","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/0008-5472.CAN-21-2463","article-title":"Cardiac dysfunction promotes cancer progression via multiple secreted factors","volume":"82","author":"Awwad","year":"2022","journal-title":"Cancer Res"},{"key":"2026080801412374700_ejhf3636-bib-0121","doi-asserted-by":"crossref","DOI":"10.3390\/cells11071108","article-title":"Cardiac remodeling in the absence of cardiac contractile dysfunction is sufficient to promote cancer progression","volume":"11","author":"Awwad","year":"2022","journal-title":"Cells"},{"key":"2026080801412374700_ejhf3636-bib-0122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2021.09.008","article-title":"Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis","volume":"163","author":"Koelwyn","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0123","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/eurjpc\/zwae089","article-title":"Association of inflammatory markers with incident heart failure or cancer in the HUNT3 and Health ABC population studies","volume":"31","author":"Bertero","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026080801412374700_ejhf3636-bib-0124","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/cvr\/cvab282","article-title":"Cardiovascular disease related circulating biomarkers and cancer incidence and mortality: Is there an association?","volume":"118","author":"Jovani","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0125","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","article-title":"Common risk factors for heart failure and cancer","volume":"115","author":"Meijers","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026080801412374700_ejhf3636-bib-0126","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ccell.2021.04.011","article-title":"Interleukin-1 in tumor progression, therapy, and prevention","volume":"39","author":"Garlanda","year":"2021","journal-title":"Cancer Cell"},{"key":"2026080801412374700_ejhf3636-bib-0127","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"10105","key":"2026080801412374700_ejhf3636-bib-0128","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"2026080801412374700_ejhf3636-bib-0129","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-19-3176","article-title":"Inhibition of IL1\u03b2 by canakinumab may be effective against diverse molecular subtypes of lung cancer: An exploratory analysis of the CANTOS trial","volume":"80","author":"Wong","year":"2020","journal-title":"Cancer Res"},{"key":"2026080801412374700_ejhf3636-bib-0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.23.00910","article-title":"Canakinumab as adjuvant therapy in patients with completely resected non-small-cell lung cancer: Results from the CANOPY-A double-blind, randomized clinical trial","volume":"42","author":"Garon","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026080801412374700_ejhf3636-bib-0131","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2026080801412374700_ejhf3636-bib-0132","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801412374700_ejhf3636-bib-0133","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ehf2.13845","article-title":"Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis","volume":"9","author":"Pappritz","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026080801412374700_ejhf3636-bib-0134","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080801412374700_ejhf3636-bib-0135","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14062","article-title":"Efficacy and safety of inhibiting the NLRP3\/IL-1beta\/IL-6 pathway in patients with ST-elevation myocardial infarction: A meta-analysis","volume":"53","author":"He","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"2026080801412374700_ejhf3636-bib-0136","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jacbts.2021.08.006","article-title":"Targeting the inflammasome in cardiovascular disease","volume":"7","author":"Olsen","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"2026080801412374700_ejhf3636-bib-0137","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12964-023-01235-9","article-title":"Divergent functions of NLRP3 inflammasomes in cancer: A review","volume":"21","author":"Shadab","year":"2023","journal-title":"Cell Commun Signal"},{"key":"2026080801412374700_ejhf3636-bib-0138","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018772","article-title":"Immuno-cardio-oncology: Killing two birds with one stone?","volume":"13","author":"Van Linthout","year":"2022","journal-title":"Front Immunol"},{"key":"2026080801412374700_ejhf3636-bib-0139","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/ehf2.12760","article-title":"Serum alarmin S100A8\/S100A9 levels and its potential role as biomarker in myocarditis","volume":"7","author":"Muller","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026080801412374700_ejhf3636-bib-0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCHEARTFAILURE.117.004125","article-title":"Pathogenic role of the damage-associated molecular patterns S100A8 and S100A9 in Coxsackievirus B3-induced myocarditis","volume":"10","author":"Muller","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026080801412374700_ejhf3636-bib-0141","doi-asserted-by":"crossref","first-page":"36535","DOI":"10.18632\/oncotarget.5440","article-title":"Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9","volume":"6","author":"Low","year":"2015","journal-title":"Oncotarget"},{"key":"2026080801412374700_ejhf3636-bib-0142","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/CIRCRESAHA.120.315865","article-title":"S100A9 links inflammation and repair in myocardial infarction","volume":"127","author":"Marinkovic","year":"2020","journal-title":"Circ Res"},{"key":"2026080801412374700_ejhf3636-bib-0143","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ehf2.14402","article-title":"Recognizing early signs in the translational phase is essential for drug development in cardiovascular medicine","volume":"10","author":"Papp","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026080801412374700_ejhf3636-bib-0144","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1161\/CIRCULATIONAHA.115.017443","article-title":"Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"2026080801412374700_ejhf3636-bib-0145","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.884174","article-title":"Differential expression of epigenetic modifiers in early and late cardiotoxic heart failure reveals DNA methylation as a key regulator of cardiotoxicity","volume":"10","author":"Robinson","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026080801412374700_ejhf3636-bib-0146","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1093\/eurheartj\/ehae188","article-title":"Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1\u03b1","volume":"45","author":"Zhou","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080801412374700_ejhf3636-bib-0147","article-title":"A heart-breast cancer-on-a-chip platform for disease modeling and monitoring of cardiotoxicity induced by cancer chemotherapy","volume":"17","author":"Lee","year":"2021","journal-title":"Small"},{"key":"2026080801412374700_ejhf3636-bib-0148","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cmet.2015.07.008","article-title":"Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure","volume":"22","author":"Nickel","year":"2015","journal-title":"Cell Metab"},{"key":"2026080801412374700_ejhf3636-bib-0149","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1534\/g3.119.400232","article-title":"Doxorubicin-induced cardiotoxicity in collaborative cross (CC) mice recapitulates individual cardiotoxicity in humans","volume":"9","author":"Zeiss","year":"2019","journal-title":"G3 (Bethesda)"},{"key":"2026080801412374700_ejhf3636-bib-0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"2026080801412374700_ejhf3636-bib-0151","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCRESAHA.121.319901","article-title":"Sex-specific cardiovascular risks of cancer and its therapies","volume":"130","author":"Wilcox","year":"2022","journal-title":"Circ Res"},{"key":"2026080801412374700_ejhf3636-bib-0152","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/ejhf.3284","article-title":"Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Rosano","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026080801412374700_ejhf3636-bib-0153","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.stemcr.2022.10.017","article-title":"Modeling sex differences in humans using isogenic induced pluripotent stem cells","volume":"17","author":"Waldhorn","year":"2022","journal-title":"Stem Cell Reports"},{"key":"2026080801412374700_ejhf3636-bib-0154","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12265-020-09962-x","article-title":"Human in vitro models for assessing the genomic basis of chemotherapy-induced cardiovascular toxicity","volume":"13","author":"Pinheiro","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"2026080801412374700_ejhf3636-bib-0155","article-title":"Racial disparity in anthracycline-induced cardiotoxicity in breast cancer patients","volume":"11","author":"Balaji","year":"2023","journal-title":"Biomedicine"},{"key":"2026080801412374700_ejhf3636-bib-0156","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: Practical considerations","volume":"62","author":"D'Arienzo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026080801412374700_ejhf3636-bib-0157","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc2127","article-title":"Insights from transgenic mouse models of ERBB2-induced breast cancer","volume":"7","author":"Ursini-Siegel","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2026080801412374700_ejhf3636-bib-0158","article-title":"Porcine-human glioma xenograft model. Immunosuppression and model reproducibility","volume":"38","author":"Hoopes","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"2026080801412374700_ejhf3636-bib-0159","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaccao.2022.12.008","article-title":"Genetic predisposition to cardiovascular disease in patients with cancer: A clinical perspective","volume":"5","author":"Farmakis","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026080801412374700_ejhf3636-bib-0160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaccao.2023.11.008","article-title":"Functional validation of doxorubicin-induced cardiotoxicity-related genes","volume":"6","author":"Fonoudi","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026080801412374700_ejhf3636-bib-0161","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.stem.2021.08.006","article-title":"RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy","volume":"28","author":"Magdy","year":"2021","journal-title":"Cell Stem Cell"},{"key":"2026080801412374700_ejhf3636-bib-0162","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.121.055801","article-title":"Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity","volume":"145","author":"Magdy","year":"2022","journal-title":"Circulation"},{"key":"2026080801412374700_ejhf3636-bib-0163","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jacbts.2017.09.002","article-title":"Overcoming the declining trends in innovation and investment in cardiovascular therapeutics: Beyond EROOM's law","volume":"2","author":"Van Norman","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"2026080801412374700_ejhf3636-bib-0164","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cpt.691","article-title":"Occlusion in the flow of new drugs for cardiovascular disease","volume":"102","author":"Ringel","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026080801412374700_ejhf3636-bib-0165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/cpt.730","article-title":"Evaluation of therapeutics for advanced-stage heart failure and other severely-debilitating or life-threatening diseases","volume":"102","author":"Prescott","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026080801412374700_ejhf3636-bib-0166","volume-title":"Drug Approval Trends: Significant Acceleration in Recent Years","author":"Walker"},{"key":"2026080801412374700_ejhf3636-bib-0167","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e27258","article-title":"Exploring the entrepreneurial landscape of university-industry collaboration on public university spin-off creation: A systematic literature review","volume":"10","author":"Romero-Sanchez","year":"2024","journal-title":"Heliyon"},{"key":"2026080801412374700_ejhf3636-bib-0168","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1073\/pnas.1404094111","article-title":"Changing the academic culture: Valuing patents and commercialization toward tenure and career advancement","volume":"111","author":"Sanberg","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026080801412374700_ejhf3636-bib-0169","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026080801412374700_ejhf3636-bib-0170","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/eurheartj\/ehae333","article-title":"Inflammation in cardio-oncology: Beyond immunotherapies","volume":"45","author":"Ferrara","year":"2024","journal-title":"Eur Heart J"},{"key":"2026080801412374700_ejhf3636-bib-0171","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.947267","article-title":"Left ventricle- and skeletal muscle-derived fibroblasts exhibit a differential inflammatory and metabolic responsiveness to interleukin-6","volume":"13","author":"Matz","year":"2022","journal-title":"Front Immunol"},{"key":"2026080801412374700_ejhf3636-bib-0172","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/cvr\/cvz024","article-title":"Personalized medicine in cardio-oncology: The role of induced pluripotent stem cell","volume":"115","author":"Sayed","year":"2019","journal-title":"Cardiovasc Res"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/6\/1028\/66824826\/eurjhf_27_6_1028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/6\/1028\/66824826\/eurjhf_27_6_1028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:41:52Z","timestamp":1786167712000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/6\/1028\/8468420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":172,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3,11]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3636","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"2024-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}